AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Taniguchi, Hirokazu; Yamada, Tadaaki; Wang, Rong; Tanimura, Keiko; Adachi, Yuta; Nishiyama, Akihiro; Tanimoto, Azusa; Takeuchi, Shinji; H. Araujo, Luiz; Boroni, Mariana; Yoshimura, Akihiro; Shiotsu, Shinsuke; Matsumoto, Isao; Watanabe, Satoshi; Kikuchi, Toshiaki; Miura, Satoru; Tanaka, Hiroshi; Kitazaki, Takeshi; Yamaguchi, Hiroyuki; Mukae, Hiroshi; Uchino, Junji; Uehara, Hisanori; Takayama, Koichi; Yano, Seiji

doi:10.1038/s41467-018-08074-0

Public

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Published in Nature Communications • Jan 10, 2019

Authors:

Hirokazu Taniguchi

Tadaaki Yamada

Rong Wang

Abstract

A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback ...

Subject

Osimertinib

Lung cancer

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!